Trial Profile

Study of tenofovir‐based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 May 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tenofovir disoproxil fumarate (Primary) ; Lamivudine
Indications Hepatitis B
Focus Adverse reactions; Therapeutic Use
Acronyms TDF-109

Most Recent Events

02 May 2018 New trial record
01 Jun 2017 A total of 59 patients completed the first phase of the study and 54/59 were enrolled over into a long-term prospective open-label study of TDF with or without LAM 300 mg daily, as per the results published in the Liver International.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com